论文部分内容阅读
Goldsmith DR等人对多沙唑嗪控释片治疗良性前列腺增生症(BPH)的疗效和安全性进行了同顾。多沙唑嗪作为一种治疗伴有下尿路症状(LUTS)的良性前列腺增生症(BPH)患者的成熟药物,目前已经有多沙唑嗪缓释剂型上市,即多沙唑嗪胃肠道治疗系统(GITS,多沙唑嗪控释片)。与传统剂型相比,多沙唑嗪控释片在药代动力学上有所改进,实现了更大首次剂量和更少的剂量调整以更快地达到临床有效剂量。在2项对BPH患者的大型、双盲、随机研究中(其中1项为安慰剂对照),多沙唑嗪控释片(4~8mg,1次/d)与传统剂型(2~8mg,1次/d)具有相同的有效性,且疗效均好于安慰剂,经过13周治疗后,IPSS评分、与健康相关的生活质量(HR-QOL)、最大尿流率均有改善。在临床研究中,BPH患者对多沙唑嗪控释片的耐受性至少与传统剂型一样好。
Goldsmith DR and colleagues have treated the efficacy and safety of doxazosin controlled-release tablets in the treatment of benign prostatic hyperplasia (BPH). Doxazosin is a mature drug for the treatment of benign prostatic hyperplasia (BPH) in patients with lower urinary tract symptoms (LUTS). Currently, there are already many forms of doxazosin sustained-release dosage forms listed as doxazosin gastrointestinal tract Treatment System (GITS, doxazosin controlled release tablets). Doxazosin controlled release tablets have improved pharmacokinetics compared to traditional dosage forms, enabling larger first dose and fewer dose adjustments to achieve clinically effective doses more quickly. In two large, double-blind, randomized trials of BPH (1 of which was a placebo control), doxazosin controlled-release tablets (4-8 mg once daily) 1 / d) had the same efficacy and efficacy as placebo. IPSS score, health-related quality of life (HR-QOL), and maximal urinary flow rate improved after 13 weeks of treatment. In clinical studies, patients with BPH are more tolerant of doxazosin-controlled tablets than traditional dosage forms.